Warangkana Chantima

490 total citations
22 papers, 298 citations indexed

About

Warangkana Chantima is a scholar working on Infectious Diseases, Molecular Biology and Immunology. According to data from OpenAlex, Warangkana Chantima has authored 22 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 7 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Warangkana Chantima's work include SARS-CoV-2 and COVID-19 Research (14 papers), COVID-19 Clinical Research Studies (8 papers) and Animal Virus Infections Studies (4 papers). Warangkana Chantima is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (14 papers), COVID-19 Clinical Research Studies (8 papers) and Animal Virus Infections Studies (4 papers). Warangkana Chantima collaborates with scholars based in Thailand, United Kingdom and United States. Warangkana Chantima's co-authors include Tararaj Dharakul, Natpapas Wiriyachaiporn, Suwussa Bamrungsap, Chayachon Apiwat, Juthathip Mongkolsapaya, Thaneeya Duangchinda, Nasamon Wanlapakorn, Preeyaporn Vichaiwattana, Natthinee Sudhinaraset and Nungruthai Suntronwong and has published in prestigious journals such as Nature Communications, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Warangkana Chantima

22 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Warangkana Chantima Thailand	10	179	98	74	43	39	22	298
Sara Caldrer Italy	8	168 0.9×	60 0.6×	27 0.4×	35 0.8×	47 1.2×	19	355
Vivian Chih-Wei Chen Singapore	2	696 3.9×	98 1.0×	65 0.9×	32 0.7×	70 1.8×	3	729
Susanne Bogers Netherlands	8	296 1.7×	148 1.5×	50 0.7×	127 3.0×	41 1.1×	16	479
Chunyun Sun China	9	131 0.7×	53 0.5×	49 0.7×	36 0.8×	51 1.3×	17	281
Sawsan S. Alamri Saudi Arabia	10	227 1.3×	68 0.7×	21 0.3×	42 1.0×	38 1.0×	22	357
Diane Yang United States	4	430 2.4×	68 0.7×	41 0.6×	21 0.5×	43 1.1×	6	465
Charles Kevin Tiu Singapore	3	765 4.3×	108 1.1×	72 1.0×	42 1.0×	76 1.9×	4	811
Shangen Zheng China	9	488 2.7×	163 1.7×	165 2.2×	41 1.0×	50 1.3×	28	657
Pattama Torvorapanit Thailand	13	196 1.1×	52 0.5×	44 0.6×	138 3.2×	35 0.9×	32	370
Deleah Pettie United States	5	562 3.1×	134 1.4×	30 0.4×	52 1.2×	78 2.0×	5	654

Countries citing papers authored by Warangkana Chantima

Since Specialization

Citations

This map shows the geographic impact of Warangkana Chantima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Warangkana Chantima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Warangkana Chantima more than expected).

Fields of papers citing papers by Warangkana Chantima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Warangkana Chantima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Warangkana Chantima. The network helps show where Warangkana Chantima may publish in the future.

Co-authorship network of co-authors of Warangkana Chantima

This figure shows the co-authorship network connecting the top 25 collaborators of Warangkana Chantima. A scholar is included among the top collaborators of Warangkana Chantima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Warangkana Chantima. Warangkana Chantima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suntronwong, Nungruthai, Sitthichai Kanokudom, Thaneeya Duangchinda, et al.. (2025). Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections. Scientific Reports. 15(1). 1454–1454. 3 indexed citations

Suntronwong, Nungruthai, Suvichada Assawakosri, Sirapa Klinfueng, et al.. (2025). Age associated SARS-CoV-2 immune responses provide insights into population immunity over four years since the COVID-19 pandemic. Scientific Reports. 15(1). 23183–23183. 1 indexed citations

Suntronwong, Nungruthai, Sitthichai Kanokudom, Chompoonut Auphimai, et al.. (2024). Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection. Vaccines. 12(2). 180–180. 3 indexed citations

Kanokudom, Sitthichai, Jira Chansaenroj, Nungruthai Suntronwong, et al.. (2024). Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study. Vaccine X. 20. 100538–100538. 1 indexed citations

Suntronwong, Nungruthai, Sitthichai Kanokudom, Suvichada Assawakosri, et al.. (2023). Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity. International Journal of Infectious Diseases. 134. 18–22. 4 indexed citations

Assawakosri, Suvichada, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.. (2023). Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination. Heliyon. 10(1). e23892–e23892. 5 indexed citations

Wanlapakorn, Nasamon, Sitthichai Kanokudom, Jira Chansaenroj, et al.. (2023). Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years. Journal of Medical Virology. 95(5). e28758–e28758. 3 indexed citations

Assawakosri, Suvichada, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.. (2022). Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. The Journal of Infectious Diseases. 226(8). 1372–1381. 41 indexed citations

Assawakosri, Suvichada, Sitthichai Kanokudom, Jira Chansaenroj, et al.. (2022). Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. International Journal of Infectious Diseases. 122. 793–801. 13 indexed citations

10.

Suntronwong, Nungruthai, Suvichada Assawakosri, Sitthichai Kanokudom, et al.. (2022). Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination. Diagnostics. 12(8). 1781–1781. 13 indexed citations

11.

Suntronwong, Nungruthai, Ritthideach Yorsaeng, Jiratchaya Puenpa, et al.. (2022). COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron. Vaccines. 10(3). 391–391. 13 indexed citations

12.

Kanokudom, Sitthichai, Suvichada Assawakosri, Nungruthai Suntronwong, et al.. (2022). Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine. 40(39). 5657–5663. 7 indexed citations

13.

Toh, Zheng Quan, et al.. (2022). Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination. Frontiers in Immunology. 13. 1010835–1010835. 9 indexed citations

14.

Suntronwong, Nungruthai, Sitthichai Kanokudom, Chompoonut Auphimai, et al.. (2022). Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination. Journal of Medical Virology. 94(12). 5713–5722. 21 indexed citations

15.

Wessel, Alex W., Nurgun Kose, Robin Bombardi, et al.. (2020). Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. Nature Communications. 11(1). 5278–5278. 39 indexed citations

16.

Saiviroonporn, Pairash, et al.. (2018). Anti-EpCAM scFv gadolinium chelate: a novel targeted MRI contrast agent for imaging of colorectal cancer. Magnetic Resonance Materials in Physics Biology and Medicine. 31(5). 633–644. 4 indexed citations

17.

Chantima, Warangkana, Charin Thepthai, Pornsuk Cheunsuchon, & Tararaj Dharakul. (2017). EpCAM expression in squamous cell carcinoma of the uterine cervix detected by monoclonal antibody to the membrane-proximal part of EpCAM. BMC Cancer. 17(1). 811–811. 15 indexed citations

18.

Chantima, Warangkana, et al.. (2016). Production, characterization, and in vitro effects of a novel monoclonal antibody against Mig-7. Biochemical and Biophysical Research Communications. 475(2). 149–153. 3 indexed citations

19.

Wiriyachaiporn, Natpapas, et al.. (2012). Combined gold nanoparticle-antibody conjugate enhances sensitivity of influenza a antigen detection in lateral flow assay. 29. 36–40. 2 indexed citations

20.

Thepthai, Charin, et al.. (2012). Improved sensitivity of influenza A antigen detection using a combined NP, M, and NS1 sandwich ELISA. Journal of Virological Methods. 185(1). 24–31. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact